Intellectual Property
Immuron has a policy to identify, capture and protect all relevant intellectual property associated within its core business strategies. The company has a long history of decisively managing its intellectual property, using in-house IP specialists and external patent and trademark attorney firms located both globally and within Australia.
Immuron manages four separate families of patent cases, requiring prosecution in each of the major global jurisdictions. All such cases are in different stages of development and prosecution. The company further maintains a significant register of trademarks, particularly in association with the product Travelan.
Due to the practical nature of the technology used to produce Travelan, the company also retains a significant amount of know-how and other unregistered intellectual property which presents significant hurdles to competitors in producing the same products. In its relationships with Hadasit and the Monash University, the company continues its policy of actively in-licensing and filing upon new technology that relates to all relevant business objectives.
Immuron currently has a suite of 30 patents either approved or pending that cover the full spectrum of its Technology Platform.
|
Travelan ETEC: Composition and Method for the Treatment and Prevention of Enteric Bacterial Infections |
|||
|
Number |
Country |
Status |
Expiry |
|
2004216920 |
Australia |
Granted |
4 March 2024 |
|
0408085-8 |
Brazil |
Pending |
4 March 2024 |
|
2,517,911 |
Canada |
Granted |
4 March 2024 |
|
201210055406.0 |
China |
Pending |
4 March 2024 |
|
04716992.5 |
Europe |
Pending |
4 March 2024 |
|
230,664 |
India |
Granted |
4 March 2024 |
|
542088 |
New Zealand |
Granted |
4 March 2024 |
|
10/548,156 |
USA |
Granted |
4 March 2024 |
|
14/138,834 |
USA |
Pending |
4 March 2024 |
|
‘LPS1’ Anti LPS Enriched Immunoglobulin Preparation For Use In Treatment and/or Prophylaxis Of A Pathologic Disorder |
|||
|
Number |
Country |
Status |
Expiry |
|
2010243205 |
Australia |
Granted |
27 April 2030 |
|
PI1014774-8 |
Brazil |
pending |
27 April 2030 |
|
2760096 |
Canada |
pending |
27 April 2030 |
|
201171304 |
Eurasia |
Issued |
27 April 2030 |
|
13/265,252 |
USA |
Published |
27 April 2030 |
|
10721856.2 |
Europe |
Published |
27 April 2030 |
|
12103554.8 |
Hong Kong |
Published |
27 April 2030 |
|
315924 |
Israel |
Allowed |
27 April 2030 |
|
2012-507877 |
Japan |
Granted |
27 April 2030 |
|
10-2011-7027634 |
South Korea |
Issued |
27 April 2030 |
|
MX/a/2011/011376 |
Mexico |
Published |
27 April 2030 |
|
‘LPS2’ Anti LPS Enriched Immunoglobulin Preparation For Use In Treatment and/or Prophylaxis of a Pathologic Disorder |
|||
|
Number |
Country |
Status |
Expiry |
|
2011290478 |
Australia |
Granted |
27 April 2030 |
|
2808361 |
Canada |
Pending |
27 April 2030 |
|
11793860.5 |
Europe |
Validated |
27 April 2030 |
|
9,943,597 |
USA |
Issued |
27 April 2030 |
|
IMM 529 Methods and Compositions for the Treatment and/or Prophylaxis of Clostridium Difficile Associated Disease |
|||
|
Number |
Country |
Status |
Expiry |
|
2014253685 |
Australia |
Pending |
19 April 2034 |
|
2,909,636 |
Canada |
Pending |
19 April 2034 |
|
2986316 |
Europe |
Pending |
19 April 2034 |
|
14/785,527 |
USA |
Pending |
19 April 2034 |
|
201480034857.3 |
China |
Pending |
19 April 2034 |
|
713233 |
NZ |
Pending |
19 April 2034 |
